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Abstract
National Immunization Technical Advisory Groups (NITAGs) provide independent, evidence-
informed advice to assist their governments in immunization policy formation. However, many 
NITAGs face challenges in fulfilling their roles. Hence the many requests for formation of a 
network linking NITAGs together so they can learn from each other. To address this request, the 
Health Policy and Institutional Development (HPID) Center (a WHO Collaborating Center at the 
Agence de Médecine Préventive - AMP), in collaboration with WHO, organized a meeting in 
Veyrier-du-Lac, France, on 11 and 12 May 2016, to establish a Global NITAG Network (GNN). 
The meeting focused on two areas: the requirements for (a) the establishment of a global NITAG 
collaborative network; and (b) the global assessment/evaluation of the performance of NITAGs. 35 
participants from 26 countries reviewed the proposed GNN framework documents and NITAG 
performance evaluation. Participants recommended that a GNN should be established, agreed on 
its governance, function, scope and a proposed work plan as well as setting a framework for 
NITAG evaluation.
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1. Introduction
The Global Vaccine Action Plan states as Strategic Objective 1 that “All countries commit to 
immunization as a priority” [1]. In support of this, National Immunization Technical 
Advisory Groups (NITAGs) provide independent, evidence-informed advise on the entire 
range of vaccines suited to the population across the age range that can assist the 
government’s immunization policy formation [2]. The contributions of NITAGs are now 
well recognized and valued by high-income countries and at the global level. However, in 
some low- and middle-income, NITAGs are still lacking or face significant challenges [3–5]. 
The Health Policy and Institutional Development Unit (HPID) of the Agence de Médecine 
Préventive (AMP) is a World Health Organization Collaborating Center on evidence-
informed immunization policy-making that was tasked in 2008 with supporting the 
establishment and strengthening of NITAGs in low-income countries, the Supporting 
Immunization and Vaccine Advisory Committees (SIVAC) Initiative [6]. At the request of 
many countries, the NITAG Resource Center (NRC) was revamped by HPID in 2015 to 
serve as a platform for exchanges across NITAGs [7–9]. While this is seen as a useful tool 
and a positive step forward, many NITAGs called for the establishment of a network of 
NITAGs to allow experiences and lessons learned to be more readily shared and discussed; 
i.e., to go beyond the sharing of documents on the NRC.
In order to address this request, the AMP-HPID Center organized, in collaboration with 
WHO, a meeting in Veyrier-du-Lac, France, the 11 and 12 May 2016, to establish a Global 
NITAG Network (GNN). This meeting focused on two areas: the requirements for (a) the 
establishment of a global NITAG Collaborative Network; and (b) the global assessment/
evaluation of NITAG performance.
To facilitate discussion and make the meeting more manageable from a logistics and cost 
perspective, the number of countries invited was limited. Countries were selected based on 
several criteria the functionality of their NITAG, income, geographic location, regional 
influence, and eligibility for SIVAC support. The invitations were sent to the NITAG Chair 
or country via email, either directly or through the WHO regional office. Most of the 
countries were interested in attending. Invitations were sent to 46 countries; 26 were able to 
attend with 18 of these sponsored by AMP-HPID and WHO. The remaining eight attending 
countries self-funded. Amongst the 20 invited countries not attending, the main reasons 
given were lack of funding/sponsorship, calendar conflicts with country internal program 
meetings, administrative obstacles and/or visa and last minute plane complications. 
Countries with NITAGs were represented by their NITAG Chair and/or Secretariats, and 
countries without a formal NITAG (three in total) sent the relevant staff as designated by 
their Ministry of Health. Appendix A lists participants by countries as well as 
representatives from the organizing, partner and donor institutions that attended.
In advance of the meeting, the AMP-HPID Center circulated a draft document that provided 
an overview of the proposed principles, functions, roles and governance of a GNN to serve 
as a template for discussion. Similarly, a tool for assessing and evaluating a NITAG’s 
performance was developed and circulated in advance to participants. We report here on the 
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outcome and recommendations from this workshop as well as the results of a participant 
questionnaire about the proposed GNN and NITAG evaluation.
2. Materials and methods
Presentations from the meeting have been made available at the NITAG Resource center 
<http://www.nitag-resource.org/fr/mediatheque/resultats-de-recherche?
document_type=54&topic=37&disease=&geographical_area=&sort=recent&offset=0>.
2.1. Day 1: GNN establishment
Plenary sessions: The meeting began with a discussion of the proposed GNN principles, 
roles, management and governance. Presenters from WHO and other partner institutions 
gave an overview of global recommendations on NITAGs and the challenges in meeting 
these. This was followed by presentations on the budding regional NITAG networks in 
Europe and in South-East Asia including their mandates and other perspectives. The plenary 
session concluded with an overview of the NRC, the online platform that could serve as a 
backbone for such networks.
Small group discussions: Country representatives then gathered in breakout sessions with 
balanced groups of 10 and 11 persons to discuss the pre-circulated draft GNN strategic 
document. They suggested revisions to the GNN’s format, mandate, roles, governance and 
discussed funding risks and opportunities.
GNN Survey: Participants were then surveyed to assess their perceptions about a global 
network, their level of interest and the desired outcome. Participants were asked to rate the 
importance of a global network for their own country’s NITAG and globally for NITAGs on 
a four items Liekert scale [10]: Extremely important; quite important; fairly important; not 
important at all.
2.2. Day 2: NITAG evaluation
Plenary sessions: The second day started with a presentation on the NITAG evaluation tool 
developed by AMP-HPID and partners, followed by presentations from countries on their 
NITAG evaluation experiences and by plenary discussions.
Small group discussions: Participants then met in breakout groups to discuss their NITAG 
requirements for performance evaluation and the possible forms of support expected from 
the GNN and partners in this regard.
Participants from donor and technical partner organizations were briefed beforehand so that 
they could facilitate, guide and help summarize the breakout group’ discussions during the 
plenary.
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3. Results: Observations and recommendations from the meeting
3.1. Global NITAG network establishment
As shown in Fig. 1, participants considered the establishment of a GNN of high importance 
for their own NITAG. 16/35 participants (45.7%) rated it as “extremely important” and 
17/35 (48.5%) as “quite important”. With respect to the importance of the GNN for ensuring 
quality of NITAGs globally, as shown in Fig. 2, 28/35 participants (80%) rated it as 
“extremely important”.
After reviewing the draft document on the establishment of a GNN, participants highlighted 
a number of key points.
3.1.1. Background and rationale—NITAGs are currently not well connected and many 
face challenges that inter-NITAG relationships might help to address e.g. a lack of expertise 
and capacity building needs. A GNN can facilitate such relationships, but there would need 
to be a clear rationale, vision and mission as well as a coordinating body if the GNN is to be 
accepted and function well. For NITAG participation to be maximized, joining the GNN 
must not increase the burden on individual countries’ NITAGs and must facilitate and 
support NITAGs but not drive their national agendas. Contributions must be voluntary and 
made in accordance with each country’s abilities and permissions. The GNN would also 
work more smoothly if roles and interactions between the GNN and the regional NITAG 
networks, where they exist, are clarified in advance so that the GNN does not duplicate or 
act as a replacement for a country NITAG nor limit the value of regional networks.
3.1.2. Values and principles—Every NITAG has something valuable to share. 
Membership in the GNN should be free of charge and voluntary, as should be collaboration 
and sharing of information. Inter-relationships between NITAGs must not be forced or 
prescriptive. Each country alone must decide on the confidentiality of their various NITAG-
related documents i.e. which can and cannot be shared. The GNN must accept that there are 
different levels of confidentiality of documents to be shared across NITAGs. Active 
exchange of information encouraged by the GNN Secretariat (see below) rather than current 
simple passive sending of files through the NRC is recommended. Capacity-building 
activities are also needed. These could potentially be more efficient and effective if thought 
about at a global rather than regional or local level. Participants highlighted the value of 
interactions with their direct geographic neighbors, as well as the importance of 
opportunities to learn from NITAGs in similar economic settings or from those speaking the 
same language( s).
3.1.3. Governance and coordination—A Board of a reasonable size with both a 
steering and an advisory role is required to lead the activities of the GNN. The Board’s ideal 
composition was not determined but participants suggested that it could be composed of 
NITAG representatives with a regular rotation of membership. Criteria could be set to guide 
the choice of countries, the inclusion of representatives from regional networks as well as 
the rotation time. Straightforward guidelines are also needed to inform the setting of the 
GNN’s priorities and agenda items. These tasks would be coordinated and managed by the 
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GNN Secretariat. The majority of participants suggested that the HPID Center at AMP may 
serve as the GNN Secretariat considering its role as a WHO CC.
The roles of the GNN’s Board would involve strategic direction setting, increasing the 
GNN’s visibility as well as fundraising for the GNN’s functioning and activities.
The need to raise funds for the GNN was considered essential. The South East Asia NITAG 
funding model, in which countries fund their own participation in Network meetings and the 
host country chairs the meeting and facilitates the logistics, was not seen as viable for all 
countries. Participants emphasized that mobilizing resources needs to (a) reflect the 
governing principles of the GNN and (b) should not be charged per country. Strategies for 
funding and securing support for the GNN is expected to be a major initial focus for the 
GNN Board and Secretariat.
3.1.4. GNN assessment—The participants agreed that it would be critical to monitor and 
evaluate the GNN in a regular and practical way. A baseline needs-assessment should be 
conducted so that the true impact can be measured later. For example, the way the GNN 
work plan items fit in with, and respond to the needs of individual countries is crucial. A few 
methods were proposed to systematically assess functioning and ensure usefulness of the 
GNN, such as the measurement of time and cost-savings for member NITAGs, satisfaction 
surveys, recognition of contributions and a collection of examples of how countries have 
helped each other on specific topics. These measurements could also help with external 
reporting to outside funders and supporting institutions. The GNN assessment outcomes 
would also be reviewed and monitored by a steering committee and shared across the 
member countries.
3.2. NITAG evaluations
The second day of the meeting was dedicated to the critical topic of NITAG evaluations. 
Indicators previously used in NITAG evaluations assessed their operations, or their 
processes, outputs and outcomes. However, while useful [11], a more fulsome assessment 
tool was still lacking, one that could guide NITAG evaluators through the planning, conduct 
and analysis of the evaluations. Such a tool would ensure consistency and comparability of 
evaluation outputs across countries. To address this gap, and based on the lessons learned 
from previous evaluation experiences led by AMP-HPID in Mongolia, Nepal, Uganda and 
Ivory Coast and from partners [12], a NITAG evaluation tool [13] developed by the AMP-
HPID Center, was revised by WHO partners and the USCDC before circulation pre meeting 
to the participants. This evaluation tool uses a multi-dimensional approach looking 
specifically at three NITAG dimensions: NITAG functioning, the quality of its 
recommendations, and its integration into the national immunization decision-making 
processes. The tool includes a detailed questionnaire to review each aspect within these 
dimensions. It comprises guidance on (a) how to plan for a NITAG evaluation (defining a 
scope, a perspective, a plan of analysis, etc.); (b) how to adapt the questionnaire to the 
country’s context; and (c) how to analyze results and make recommendations. This tool has 
been used to evaluate NITAGs in Armenia and Moldova in 2016 [14]. The NITAG 
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evaluation tool was designed for use by external evaluators, but could also be used for self-
evaluation.
The meeting discussion on the need for a more comprehensive and standardized NITAG 
evaluation highlighted many advantages and benefits, not just for the purposes of 
accountability globally but also for their potential use in advocacy and communications at 
country level. Participants noted that results and recommendations from sequential NITAG 
evaluations could be used to demonstrate the added value of NITAGs to decision-makers. It 
was acknowledged that some countries might not permit sharing or publishing of the their 
country’s evaluation but countries could still provide feedback on the tool itself through the 
GNN Secretariat. The NITAG evaluation tool could also help an individual country’s NITAG 
to compare itself with NITAGs in other similar or different countries.
Two main themes emerged from the discussion on NITAG evaluations: firstly, the need to 
form a pool of trained evaluators and, secondly, the need to raise awareness of the benefits of 
NITAG evaluations, at a minimum to the NITAG Chairperson, Secretariats and members. 
The Network could facilitate the training of trainers. A guide for evaluators or a short 
introduction module would be helpful to facilitate the use of the tool. It was noted that it 
may be of more value for the evaluation to be conducted by an individual who is familiar 
with the way the NITAG functions rather than an expert in evaluations as the NITAG tool 
itself guides the evaluator through each of the steps of the evaluation. The more critical 
aspect of the evaluation rests in the interpretation of the findings, and for this an 
understanding and knowledge of NITAG work and functioning is crucial. Twenty-two 
participants agreed to be included in the pool of trainers who will help NITAGs to conduct 
their evaluation.
Participants agreed on the value of systematically evaluating their NITAG using the tool 
presented. Furthermore, they were committed to sharing the results of the evaluations. 
Participants suggested that, although an independent evaluation is important, countries 
should be encouraged to conduct an initial self-assessment (if possible) to adjust their 
functioning prior to external evaluation. They could subsequently request support from 
partners for external evaluation if needed. Partners can provide technical assistance but 
countries should favor local solutions as much as possible to reduce costs. Other “local” 
solutions could include working with neighboring countries to provide low-cost assistance.
Participants agreed to provide feedback and/or share results on the NITAG evaluation tool, 
either by email immediately after the meeting or once they have used it internally. A 
template will need to be developed to facilitate and systematize feedback from countries.
Overall, the assembly recommended that NITAGs should:
– Consider the relevance of conducting a self-evaluation before engaging in a 
larger external evaluation.
– Share their evaluation results (via the NRC).
– Document the implementation of their evaluation and the follow-up on the 
recommendations and engage in peer-to-peer support for evaluation.
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– Get support from the GNN for their evaluation via a pool of trained evaluators.
– Rely on materials developed by the Network Secretariat, to familiarize and train 
NITAGs in the evaluation process.
3.3. Next steps
The meeting participants agreed that a core group to steer the next steps will be selected 
from the countries that volunteered during the meeting, including: Albania, Argentina, 
Australia, Canada, Costa Rica, Indonesia, Mozambique, the Netherlands, Saudi Arabia, 
Senegal, the Sudan, the United Kingdom, and Uganda. The length of term for these initial 
GNN core group countries will need to be staggered, represent diversity e.g. including 
amongst developing countries and also support links to regional NITAGs.
Participants strongly recommended that each participant try to ensure that their country send 
a representative to the GNN meeting on an annual basis and that the meeting be organized 
by AMPHPID. Suggested workshop themes for upcoming meetings included methods on: 
reviews, decision-making, specific evidence-grading methodologies such as the “Grading of 
Recommendations, Assessment, Development and Evaluations (GRADE)” [15], economic 
analysis and a review of the resources and training required to do this work.
4. Discussion
This global workshop led to constructive discussions on the establishment of a GNN linking 
NITAGs around the world. The GNN would provide the opportunity for each country and 
the institutional partners to share views and challenges on NITAG work. Countries attending 
the meeting were keen to form the GNN. The meeting highlighted the value to countries of 
sharing their experiences and lessons learned in conducting NITAG work. Participants 
emphasized the value of having such an opportunity to learn from each other and to be 
officially linked within a network, with the NRC as a platform. For the GNN to work well, it 
needs to meet on a regular basis. Using a GNN to facilitate NITAG evaluation was also an 
area of high interest to all the countries attending. Despite the possibility that confidentiality 
rules may preclude the sharing of some information, overall country NITAG representatives 
felt that NITAGs should be encouraged to share evaluation results and feedback via the NRC 
to support future evaluations. Additional suggestions were made during the meeting on how 
to move forward with the GNN evaluation program such as the potential for joint NITAG 
evaluations with EPI review programs.
Discussions also highlighted the difficulty of funding future GNN activities, including 
country-specific research and training programs, operations support, IT solutions, translation 
of documents and materials and meeting costs. The fear that money from funding agencies, 
partners and high-income countries might create a conflict of interest with respect to agenda 
and priority setting was seen as a challenge to the GNN fundraising team. This might be 
mitigated with a strong management of conflict of interest policy for the GNN.
WHO and other partners noted that the global framework of the Sustainable Development 
Goals and Universal Health Coverage is an overarching environment that supports this GNN 
initiative. While only about half of the world’s currently in place NITAGs were invited to 
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attend this meeting and funding was provided for a very limited number, the breadth of 
attendance in terms of WHO regions and country income levels was very encouraging. As 
other country NITAGs learn of the GNN, it is expected that membership will expand. As the 
GNN develops, it will enable information and evidence to be leveraged not only at country 
level but also on a collaborative platform and around the globe.
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Fig. 1. 
Responses by individual meeting participants on importance of a NITAG network for their 
individual country’s NITAG.
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Fig. 2. 
Responses by individual meeting participants on the importance of an international NITAG 
network for ensuring quality of NITAGs globally.
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